You are here: Industry Insights > NICE

News List

NICE back Roche’s Tecentriq for CDF pharmatimes
November 02, 2017
The National Institute for Health and Care Excellence is recommending Roche’s Tecentriq for use within the Cancer Drugs Fund to treat advanced urothelial cancer in certain circumstances.
NICE warns against blanket use of antibiotics to treat sinus infections pharmatimes
October 30, 2017
The National Institute for Health and Care Excellence is warning against blanket use of antibiotics to treat sinus infections.
GSK's 'bubble boy' gene therapy secures NICE recommendation despite high cost pharmafile
October 26, 2017
GSK has received good news from NICE as it is revealed that Strimvelis, its gene therapy treatment for adenosine deaminase deficiency or ‘bubble boy’ syndrome, has been given a positive recommendation by NICE despite the extremely high cost associated wi
NICE bars NHS access to Lenvima, Nexavar for thyroid cancer pharmatimes
October 24, 2017
NHS treatment cost regulators have published draft guidelines rejecting funding for Eisai’s Lenvima and Bayer’s Nexavar for treating certain patients with thyroid cancer.
NICE nod for GSK’s ‘bubble baby syndrome’ gene therapy pharmatimes
October 24, 2017
The National Institute for Health and Care Excellence has published draft guidance recommending GlaxoSmithKline’s gene therapy Strimvelis as an option for treating an ultra-rare immune deficiency condition commonly referred to as bubble baby syndrome.
NICE says no for Opdivo in urothelial carcinoma pharmatimes
October 23, 2017
The National Institute for Health and Care Excellence has published draft guidelines rejecting NHS funding for Bristol-Myers Squibb’s Opdivo as a treatment for locally advanced unresectable or metastatic urothelial carcinoma (mUC).
NICE expands Bayer's Stivarga prospects with move from CDF fiercepharma
October 13, 2017
Since the National Institute for Health and Care Excellence took the reins of England’s Cancer Drugs Fund last year, several drugmakers have seen their oncology meds get the boot. Not Bayer.
NICE backing for Bayer’s Stivarga in GIST pharmatimes
October 13, 2017
Bayer’s Stivarga is being backed by the National Institute for Health and Care Excellence as a cost-effective option for the treatment of adults with gastrointestinal stromal tumours (GIST).
NICE gives final draft guidance on two key cancer drugs pharmafile
October 13, 2017
NICE has announced it has published its final draft guidance for two cancer treatments, covering Bayer’s Stivarga (regorafenib) in the treatment of gastrointestinal stromal tumours (GIST
NICE recommends access to venclyxto for adult leukaemia europeanpharmaceuticalreview
October 09, 2017
NICE has issued a final appraisal determination recommending that venclyxto is made available to patients with chronic lymphocytic leukaemia…

Previous page 1 2 3 4 5 6 7 8 9 10 ... 41 42 Next page